ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.906,08
-0,49%
S&P 500
5.942,47
1,26%
Dow Jones
42.732,13
0,80%
Euro vs US Dollar
1,02966
-0,08%
Bitcoin
98.385,03
0,08%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Cytokinetics Inc (CYTK)

  7. Cytokinetics Inc (CYTK) News

CYTK

Cytokinetics (CYTK)

Cytokinetics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CYTK
DatumZeitQuelleÜberschriftSymbolFirma
03/01/202522h00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:CYTKCytokinetics Inc
23/12/202413h30GlobeNewswire Inc.Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
20/12/202406h00GlobeNewswire Inc.Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater ChinaNASDAQ:CYTKCytokinetics Inc
17/12/202401h23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
16/12/202422h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
16/12/202422h13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
12/12/202422h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
10/12/202423h42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
10/12/202422h06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
05/12/202422h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
05/12/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
05/12/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
05/12/202422h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
05/12/202422h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
03/12/202422h00GlobeNewswire Inc.Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CYTKCytokinetics Inc
03/12/202413h30GlobeNewswire Inc.Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection FractionNASDAQ:CYTKCytokinetics Inc
03/12/202400h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
02/12/202422h01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
02/12/202422h00GlobeNewswire Inc.Cytokinetics to Participate in December Investor ConferencesNASDAQ:CYTKCytokinetics Inc
02/12/202413h30GlobeNewswire Inc.Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic CardiomyopathyNASDAQ:CYTKCytokinetics Inc
27/11/202401h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
26/11/202423h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
26/11/202422h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
25/11/202422h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
19/11/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CYTKCytokinetics Inc
19/11/202412h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CYTKCytokinetics Inc
19/11/202408h30GlobeNewswire Inc.Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in JapanNASDAQ:CYTKCytokinetics Inc
18/11/202422h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CYTKCytokinetics Inc
16/11/202415h00GlobeNewswire Inc.Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
16/11/202415h00GlobeNewswire Inc.Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024NASDAQ:CYTKCytokinetics Inc
 Showing the most relevant articles for your search:NASDAQ:CYTK

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
TG
CBK
Commerzbank
PM
XAUUSD
Gold vs US Dollar
NYSE
DIS
Walt Disney
NYSE
JPM
JP Morgan Chase
USOTC
RHHBY
Roche (QX)
DBI
MDAX
MDAX
CCOM
SILVER
SILVER
AMEX
XLV
Health Care Select Sector
NASDAQ
NVDA
NVIDIA
COIN
XRPUSD
Ripple
TG
DBK
Deutsche Bank
CCOM
US30
US 30
CCOM
US500
US 500
TG
RHM
Rheinmetall
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten